Atheneos Ventures

Atheneos Ventures is an evergreen fund that provides funding to early-stage companies rooted in the life sciences industry. It is a San Francisco Bay Area-based, healthcare-focused, evergreen fund dedicated to identifying and nurturing high quality, high risk (and potentially) game-changing healthcare companies. Previously specializing in common diseases, Atheneos Ventures forges ahead focusing on orphan drugs and rare diseases.

Sjef de Kimpe

Venture Partner

3 past transactions

Armetheon

Series B in 2015
Armetheon, Inc., is a privately held San Francisco Bay area based clinical stage biopharmaceutical company focused on the development of novel drugs for highly unmet need. The company has several programs in clinical stage of development. These include:

Armetheon

Series A in 2014
Armetheon, Inc., is a privately held San Francisco Bay area based clinical stage biopharmaceutical company focused on the development of novel drugs for highly unmet need. The company has several programs in clinical stage of development. These include:

Altheos

Series A in 2010
Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.